Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Faces Delay Of "Three To Four Months" For Latest HIV Single-Pill Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

If approved, the combination of Gilead's Truvada and J&J's TMC278 is still expected to launch this year, but impurities related to one component have resulted in a "refuse to file" letter from FDA.

You may also be interested in...



Doubling Its Bet In IPF, Gilead Buys Arresto Biosciences For $225 Million

Deal also calls for sales-based milestones, likely pegged to antibody currently in Phase I in idiopathic pulmonary fibrosis and advanced solid tumors.

Market-Based Drug Fees: IRS Will Release 2011 Estimates In May, Guidance Says

The IRS guidance proposes a method for calculating the fees and sets out a timetable for the process in 2011, the program's first year. The guidance also describes what corporate entities are liable for the fees and what branded drugs are covered.

AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia

With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel